SRRK ▼ -0.6% - Scholar Rock Holding Corporation $SRRK - Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) Scholar Rock stock declined 0.6% today despite announcing FDA approval of ISEMBYLD (apitegromab-mstn), a novel muscle-targeted treatment for spinal muscular atrophy that marks the first therapy in its class. The modest pullback suggests investors may have already priced in the approval ahead of the announcement, or are weighing near-term commercialization challenges against the significant long-term market opportunity. 11-SEP-2026 06:29 PM ET